Associate Professor - medical
Strategic program(s):
Biography
Dr. Jannick Dorresteijn is an Internist and Vascular Medicine Specialist at the University Medical Center Utrecht (UMC Utrecht), with extensive experience in cardiovascular care and clinical epidemiology. He completed his medical degree in 2009 and a Master’s in Clinical Epidemiology in 2011, both at Utrecht University. His doctoral research, partly conducted at Harvard University, focused on developing statistical algorithms to tailor preventive treatments for cardiovascular disease, facilitating shared decision-making between patients and healthcare providers. In 2013, he was awarded a PhD with honors (cum laude) for this work.
Throughout his career, Dr. Dorresteijn has contributed to major international collaborations under the leadership of the European Society of Cardiology (ESC) Cardiovascular Risk Collaboration. He has been instrumental in the development and validation of key cardiovascular risk scores, including SCORE2, SCORE2-Diabetes, and the SMART2 Risk Score. These models have been adopted into international and national clinical guidelines, helping healthcare professionals worldwide better assess and manage patients at risk of or living with cardiovascular disease.
Dr. Dorresteijn is a Co-Principal Investigator of the UCC-SMART study, a large-scale, ongoing prospective cohort study at UMC Utrecht that focuses on individuals at risk of or with established atherosclerotic cardiovascular disease (ASCVD). This study provides critical insights into cardiovascular risk factors and outcomes, contributing to the development of evidence-based preventive strategies.
Since 2018, he has led the scientific development and clinical implementation of U-Prevent.com, a web-based tool that personalizes preventive treatment for cardiovascular diseases using advanced statistical algorithms. Dr. Dorresteijn continues to drive its further development, focusing on integrating U-Prevent into electronic health record (EHR) systems to streamline its use in clinical practice. He is also expanding the algorithms to cover a wider range of patient populations, ensuring that more individuals can benefit from personalized cardiovascular prevention.
In addition to his work on U-Prevent, Dr. Dorresteijn has a strong track record in methodological innovation. His contributions include lifetime risk and treatment benefit prediction, techniques for handling missing data in clinical practice, and the flexible incorporation of additional risk factor information to improve the precision of cardiovascular risk assessments.
Dr. Dorresteijn has also held leadership roles at the national level. In 2023-2024, he served as Vice-Chair of the Cardiovascular Agenda working group of the Dutch Heart Foundation, where he helped define national priorities for cardiovascular research and care. He also chaired the Personalized Treatment working group, advocating for the integration of individualized, evidence-based approaches in cardiovascular prevention and treatment across healthcare systems.
Through his clinical work, research, and leadership, Dr. Dorresteijn continues to bridge the gap between scientific innovation and clinical practice, advancing cardiovascular care and improving patient outcomes.
